Medtronic To Pay J&J $270M Over Stent Patent Fees
Medtronic Inc. has agreed to fork over $270 million in a bid to bury the hatchet with Johnson & Johnson in a long-running dispute over royalties concerning three stent patents used...To view the full article, register now.
Already a subscriber? Click here to view full article